ArticleBiomolecules2020
On the Risks of Phylogeny-Based Strain Prioritization for Drug Discovery:
Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Karakum desert: a unique source of cultivable novel and rare actinomycetes with a remarkable biosynthetic potential.World journal of microbiology & biotechnology · 2025Article
- Evaluation ofFrontiers in microbiology · 2024Article
- A panoramic view of the genomic landscape of the genusMicrobial genomics · 2023Article
- Discovery and biosynthetic assessment of 'Microbial genomics · 2023Article
- Lunaemycins, New Cyclic Hexapeptide Antibiotics from the Cave Moonmilk-DwellerInternational journal of molecular sciences · 2023Article
- Structure of New Ferroverdins Recruiting Unconventional Ferrous Iron Chelating Agents.Biomolecules · 2022Article
- Antifungal Activity and Biosynthetic Potential of NewInternational journal of molecular sciences · 2021Article
- Article
- Genome-based classification of the Streptomyces violaceusniger clade and description of Streptomyces sabulosicollis sp. nov. from an Indonesian sand dune.Antonie van Leeuwenhoek · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Strain prioritization for drug discovery aims at excluding redundant strains of a collection in order to limit the repetitive identification of the same molecules. In this work, we wanted to estimate what can be unexploited in terms of the amount, diversity, and novelty of compounds if the search is focused on only one single representative strain of a species, taking
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.